Paroxysmal Atrial Fibrillation Clinical Trial
Official title:
Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation-MYPAF, a Randomized Controlled Three Arms Study
The main purpose of this study is to investigate effect of Medi Yoga on quality of life,
biomedical factors and health care consumption, and to study gender differences between
individuals diagnosed with paroxysmal atrial fibrillation (PAF). Furthermore, an additional
purpose is to describe people's experiences of Medi Yoga and identify how Medi Yoga affects
their condition.
Hypothesis Individuals with PAF exercising Medi Yoga improve their quality of life and blood
pressure, heart rate and heart rate variability. Biological markers such as NT-proBNP and
CRP are positively affected, and that individuals seek less medical care.
Methods / materials The chosen study design is a randomized Three arms controlled trial. The
study will be conducted at the Cardiology Clinic at Danderyd Hospital in Stockholm. One
hundred and thirty two individuals will be included and randomized to the intervention group
(yoga), Music relaxation group or control group (usual follow-up). Inclusion criteria are
the diagnosis of PAF and experience of symptomatic atrial fibrillation verified by ECG in
the last six months. Exclusion criteria are language difficulties, multi-diagnosis and/or
cognitive dysfunction (eg, diagnoses of mental illness, dementia) who are judged not to be
able to perform yoga. Individuals with persistent or permanent atrial fibrillation are also
excluded.
The subjects in the intervention group will practice yoga in groups for one hour once a week
for 12 weeks in the hospital, with the guidance of a trained yoga instructor. They will
receive written instructions on yoga exercises and a CD record to perform the yoga program
at home. Added to that, the standard treatment i.e. drugs, cardioversion or ablation. The
music relaxation group will listen to Music in half an hour in a group at the hospital.The
control group receives usual care.
Participants are followed for three months and the evaluation is done at baseline and after
three months. During these visits quality of life will be measured with two surveys, as well
as variables such as blood pressure, heart rate, biological markers (CRP , BNP) , and ECG
and 24-hour ECG . Primary endpoint: quality of life. In order to obtain a five -point
difference in the quality of life, 132 subjects are required to achieve a power of 80
percent (p-value 0.05), including a loss rate of 20 percent. The calculation is based on the
results of Substudy I. Analytical methods that will be used are: multivariate analyzes eg
logistic regression, MANOVA, etc. and univariate analyzes.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05970120 -
A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter
|
N/A | |
Recruiting |
NCT06014996 -
Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation.
|
N/A | |
Completed |
NCT03624881 -
Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
|
Phase 4 | |
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Recruiting |
NCT05905835 -
Treatment of PAF With the Synaptic System
|
N/A | |
Active, not recruiting |
NCT05534581 -
SINGLE SHOT CHAMPION
|
Phase 4 | |
Active, not recruiting |
NCT05618340 -
PFA for Paroxysmal Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT05024630 -
Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension
|
N/A | |
Completed |
NCT01913522 -
Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration
|
N/A | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Withdrawn |
NCT01917981 -
Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation
|
Phase 3 | |
Terminated |
NCT01925885 -
Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)
|
N/A | |
Completed |
NCT01693107 -
Atrial Fibrillation Force Contact Ablation Study
|
||
Completed |
NCT01842529 -
Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery
|
Phase 2 | |
Completed |
NCT00971204 -
Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
|
Phase 2 | |
Completed |
NCT05043883 -
Automated Assessment of PVI Using a Novel EP Recording System
|
N/A | |
Recruiting |
NCT05172765 -
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
|
N/A | |
Recruiting |
NCT04529785 -
Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation
|
N/A | |
Completed |
NCT04022954 -
HD Mapping of Atrial Fibrillation in Asia Pacific
|
||
Completed |
NCT00964392 -
NAVISTAR® THERMOCOOL® Catheter Post Approval Registry
|
Phase 4 |